Opening Doors To Generic Drugs With Fleming Europe, 30 - 31 May 2012, Berlin

Main Category: Conferences
Article Date: 03 Feb 2012 - 0:00 PST


New issues raised in the Generic licensing industry are going to be the center of attention at Fleming Europe's upcoming conference. Opportunities in emerging markets of BRIC countries and development in the EU will dominate the discussions held in Berlin.

The current situation in the pharmaceutical industry is turning its side with generic makers. According to the report of The Economist from December 2011, the best-selling drugs are about to fall over the patent cliff. By 2015, blockbusters' worth 130 billion euros in global annual sales will go off-patent. It presents new opportunities and challenges for generics companies and poses the highest time to start looking for the best practices in licensing activities.

Encouraged by the success of the past conferences and new industry topics on the horizon, Fleming Europe is organizing its 6th Annual Licensing in Generics Conference. Situated in Germany's capital, it is scheduled for 30 - 31 May 2012.

"The current market trends in the global generic business development and licensing in the EU, generic licensing opportunities in rising markets, the key regulatory developments influencing the business of generic companies in the EU, USA and India as well as intellectual property challenges will be in the focus of this year's conference," Simova Valigova, producer of the conference, revealed.

Prominent speakers ...

• Rahul Garella, Glenmark Generics, UK
• Ewan Livesey, Lupin Atlantis Holdings SA, Switzerland
• Ashish Menocha, Abdi Ibrahim, UK
• Mandar Kodgule, Wockhardt, India
• Mohamed Abdel Gelil, Sandoz, Egypt

... will be present to share their scientific knowledge.

This year's conference will provide a unique chance for all the delegates to build scientific networks with experts working in similar domain. Together they can face future development in the European markets and explore new opportunities raised in emerging markets.

• Additional
• References
• Citations